Cargando…
Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum]
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Dove
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480746/ https://www.ncbi.nlm.nih.gov/pubmed/32943875 http://dx.doi.org/10.2147/OTT.S278185 |
| _version_ | 1783580469276704768 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7480746 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Dove |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74807462020-09-16 Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum] Onco Targets Ther Corrigendum Dove 2020-09-04 /pmc/articles/PMC7480746/ /pubmed/32943875 http://dx.doi.org/10.2147/OTT.S278185 Text en © 2020 Sawalha et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
| spellingShingle | Corrigendum Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum] |
| title | Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum] |
| title_full | Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum] |
| title_fullStr | Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum] |
| title_full_unstemmed | Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum] |
| title_short | Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum] |
| title_sort | evaluating the therapeutic potential of zanubrutinib in the treatment of relapsed/refractory mantle cell lymphoma: evidence to date [corrigendum] |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480746/ https://www.ncbi.nlm.nih.gov/pubmed/32943875 http://dx.doi.org/10.2147/OTT.S278185 |